Bibliography
Found 43 results
Filters: Keyword is Viral Load [Clear All Filters]
Older age and plasma viral load in HIV-1 infection. AIDS. 2004 ;18 Suppl 1:S87-98.
Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of D-Ala1-peptide T-amide for HIV-1-associated cognitive-motor impairment. Journal of NeuroVirology [Internet]. 2006 ;12(3):178-89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16877299
Human immunodeficiency virus and the central nervous system. The Brazilian Journal of Infectious Diseases: An Official Publication of the Brazilian Society of Infectious Diseases [Internet]. 2006 ;10:41-50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16767315
. Immunodetection of human immunodeficiency virus type 1 (HIV-1) Vpr in brain tissue of HIV-1 encephalitic patients. Journal of Neurovirology [Internet]. 2006 ;12:200-10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16877301
. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. Journal of Neurovirology [Internet]. 2006 ;12:100-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16798671
. Crack cocaine: effect modifier of RNA viral load and CD4 count in HIV infected African American women. Frontiers in Bioscience: A Journal and Virtual Library [Internet]. 2007 ;12:1488-95. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17127396
. HIV-1 RNA concentration and cognitive performance in a cohort of HIV-positive people. AIDS (London, England) [Internet]. 2007 ;21:1415-22. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17589187
. Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol. 2008 ;64(5):566-72.
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008 ;65(1):65-70.
Low atazanavir concentrations in cerebrospinal fluid. AIDS. 2009 ;23(1):83-7.
White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol. 2009 ;15(2):187-95.
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011 ;25(14):1747-51.
Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol. 2011 ;17(3):248-57.
Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother. 2011 ;66(2):354-7.
Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011 ;17(1):50-7.
Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology. 2014 ;82(23):2055-62.
Elevated brain monoamine oxidase activity in SIV- and HIV-associated neurological disease. J Infect Dis. 2014 ;210(6):904-12.
. Evidence of the innate antiviral and neuroprotective properties of progranulin. PLoS One. 2014 ;9(5):e98184.
. Gp120 in the pathogenesis of human immunodeficiency virus-associated pain. Ann Neurol. 2014 ;75(6):837-50.
. Absence of neurocognitive effect of hepatitis C infection in HIV-coinfected people. Neurology. 2015 ;84(3):241-50.
Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS. 2015 ;29(3):323-30.
. Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol. 2015 ;21(1):56-65.
.